Enabling
Cell Therapy
Our ApoGraft™ technology turns production of cell-based therapies into a simple, safe and inexpensive process
Learn more about CellectOur ApoGraft™ technology turns production of cell-based therapies into a simple, safe and inexpensive process
Learn more about CellectJUL 2016
Cellect raises $8.4M
JAN 2017
US Patent Notice of Allowance
FEB 2017
First Cancer Patient Treated In Phase I/II Trial Positive Clinical Results
MAR 2017
Successful First Cancer Patient Stem Cell Transplant
JUN 2017
Cellect Receives Russian Patent
SEP 2017
FDA Grants Cellect Orphan Drug Status for ApoGraft™
SEP 2017
Cellect raises $4.3M
JAN 2018
Positive Clinical Trial Results100% Acceptance and Zero Related Adverse Events
JAN 2018
Cellect raises $4.0M
JAN 2018
Opening 2nd Clinical Trial Site DSMB Approves Dose Escalation
APR 2018
Successfully completes POC testing for scalable production of ApoTainer™
JUL 2018
Signs Collaboration Agreement with Dresden University
AUG 2018
Cellect Granted Key European Patent for Stem Cells Selection Technology
AUG 2018
Korean Patent
Notice of Allowance
JUL 2019
Washington University (US) clinical collaborative agreement
OCT 2019
Cellect receives an FDA IND approval
JAN 2020
Cellect raises $3.0M
APR 2020
Canadian patent granted. Overall 9 company owned patent families: 45 granted, 17 pending, 2 PCT applications
MAY 2020
Positive results of ongoing clinical trial. Robust engraftment and no safety and tolerability issues.
MAY 2020
Cellect raises $1.5M
It is all about replacing damaged tissues and organs instead of "fixing" them with drugs and radiations
The process takes weeks in specialty labs, remains highly ineffective and its costs keep stem cell treatments a privilege of the elitist-few who can afford it
